Geode Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $73M | Sell |
1,570,088
-53,426
| -3% | -$2.57M | ﹤0.01% | 1415 |
|
|
2026
Q1 | $83.9M | Buy |
1,623,514
+150,615
| +10% | +$7.67M | 0.01% | 1197 |
|
|
2025
Q4 | $73.2M | Buy |
1,472,899
+62,875
| +4% | +$3.06M | ﹤0.01% | 1267 |
|
|
2025
Q3 | $67.4M | Buy |
1,410,024
+10,414
| +0.7% | +$419K | ﹤0.01% | 1297 |
|
|
2025
Q2 | $44.1M | Buy |
1,399,610
+72,991
| +6% | +$2.34M | ﹤0.01% | 1495 |
|
|
2025
Q1 | $43.5M | Sell |
1,326,619
-183,949
| -12% | -$6.52M | ﹤0.01% | 1455 |
|
|
2024
Q4 | $54.6M | Buy |
1,510,568
+28,517
| +2% | +$1M | ﹤0.01% | 1382 |
|
|
2024
Q3 | $46.2M | Buy |
1,482,051
+74,438
| +5% | +$2.32M | ﹤0.01% | 1475 |
|
|
2024
Q2 | $37.7M | Buy |
1,407,613
+100,663
| +8% | +$2.92M | ﹤0.01% | 1546 |
|
|
2024
Q1 | $44.6M | Buy |
1,306,950
+61,796
| +5% | +$1.84M | ﹤0.01% | 1431 |
|
|
2023
Q4 | $36M | Buy |
1,245,154
+152,057
| +14% | +$4.03M | ﹤0.01% | 1544 |
|
|
2023
Q3 | $30.1M | Buy |
1,093,097
+38,951
| +4% | +$1.19M | ﹤0.01% | 1555 |
|
|
2023
Q2 | $31.7M | Buy |
1,054,146
+16,653
| +2% | +$583K | ﹤0.01% | 1547 |
|
|
2023
Q1 | $37.6M | Buy |
1,037,493
+30,946
| +3% | +$1.19M | ﹤0.01% | 1382 |
|
|
2022
Q4 | $35.9M | Buy |
1,006,547
+57,637
| +6% | +$2M | 0.01% | 1378 |
|
|
2022
Q3 | $32.1M | Buy |
948,910
+9,769
| +1% | +$318K | ﹤0.01% | 1400 |
|
|
2022
Q2 | $27.2M | Buy |
939,141
+9,134
| +1% | +$262K | ﹤0.01% | 1541 |
|
|
2022
Q1 | $30.1M | Sell |
930,007
-31,701
| -3% | -$972K | ﹤0.01% | 1609 |
|
|
2021
Q4 | $28M | Buy |
961,708
+12,695
| +1% | +$385K | ﹤0.01% | 1730 |
|
|
2021
Q3 | $25.3M | Buy |
949,013
+43,322
| +5% | +$1.16M | ﹤0.01% | 1785 |
|
|
2021
Q2 | $27.9M | Buy |
905,691
+36,067
| +4% | +$1.11M | ﹤0.01% | 1744 |
|
|
2021
Q1 | $22.8M | Buy |
869,624
+74,193
| +9% | +$2.07M | ﹤0.01% | 1794 |
|
|
2020
Q4 | $20M | Buy |
795,431
+32,373
| +4% | +$697K | ﹤0.01% | 1717 |
|
|
2020
Q3 | $15.9M | Sell |
763,058
-9,849
| -1% | -$224K | ﹤0.01% | 1686 |
|
|
2020
Q2 | $18.4M | Buy |
772,907
+14,564
| +2% | +$322K | ﹤0.01% | 1572 |
|
|
2020
Q1 | $13.6M | Buy |
758,343
+42,959
| +6% | +$903K | ﹤0.01% | 1547 |
|
|
2019
Q4 | $17M | Buy |
715,384
+20,299
| +3% | +$493K | ﹤0.01% | 1667 |
|
|
2019
Q3 | $19.1M | Buy |
695,085
+19,319
| +3% | +$572K | ﹤0.01% | 1519 |
|
|
2019
Q2 | $22.4M | Buy |
675,766
+40,936
| +6% | +$1.4M | 0.01% | 1413 |
|
|
2019
Q1 | $22.2M | Buy |
634,830
+46,571
| +8% | +$1.73M | 0.01% | 1347 |
|
|
2018
Q4 | $19.5M | Buy |
588,259
+44,268
| +8% | +$1.9M | 0.01% | 1296 |
|
|
2018
Q3 | $27.4M | Buy |
543,991
+17,366
| +3% | +$858K | 0.01% | 1180 |
|
|
2018
Q2 | $31.5M | Buy |
526,625
+27,136
| +5% | +$1.41M | 0.01% | 1034 |
|
|
2018
Q1 | $22.9M | Buy |
499,489
+34,749
| +7% | +$1.45M | 0.01% | 1170 |
|
|
2017
Q4 | $18.5M | Buy |
464,740
+15,489
| +3% | +$612K | 0.01% | 1313 |
|
|
2017
Q3 | $18M | Sell |
449,251
-5,158
| -1% | -$223K | 0.01% | 1326 |
|
|
2017
Q2 | $19.6M | Buy |
454,409
+6,585
| +1% | +$234K | 0.01% | 1200 |
|
|
2017
Q1 | $14M | Buy |
447,824
+69,395
| +18% | +$1.86M | 0.01% | 1413 |
|
|
2016
Q4 | $9.55M | Buy |
378,429
+33,954
| +10% | +$759K | ﹤0.01% | 1614 |
|
|
2016
Q3 | $8.52M | Buy |
344,475
+68,393
| +25% | +$1.55M | ﹤0.01% | 1596 |
|
|
2016
Q2 | $5.62M | Buy |
276,082
+39,895
| +17% | +$708K | ﹤0.01% | 1831 |
|
|
2016
Q1 | $3.6K | Sell |
236,187
-49,772
| -17% | -$649K | ﹤0.01% | 2086 |
|
|
2015
Q4 | $3.84M | Buy |
285,959
+2,418
| +0.9% | +$37.4K | ﹤0.01% | 2046 |
|
|
2015
Q3 | $3.98M | Buy |
283,541
+44,852
| +19% | +$834K | ﹤0.01% | 1987 |
|
|
2015
Q2 | $4.05M | Buy |
238,689
+84,484
| +55% | +$1.2M | ﹤0.01% | 2052 |
|
|
2015
Q1 | $1.86M | Buy |
154,205
+7,185
| +5% | +$67.9K | ﹤0.01% | 2486 |
|
|
2014
Q4 | $1.22M | Buy |
147,020
+522
| +0.4% | +$4.39K | ﹤0.01% | 2722 |
|
|
2014
Q3 | $1.27M | Buy |
146,498
+5,759
| +4% | +$52K | ﹤0.01% | 2638 |
|
|
2014
Q2 | $1.54M | Buy |
140,739
+55,205
| +65% | +$492K | ﹤0.01% | 2537 |
|
|
2014
Q1 | $764K | Buy |
85,534
+5,819
| +7% | +$53.6K | ﹤0.01% | 2936 |
|
|
2013
Q4 | $601K | Buy |
79,715
+19,202
| +32% | +$134K | ﹤0.01% | 2997 |
|
|
2013
Q3 | $444K | Buy |
60,513
+2,036
| +3% | +$13.7K | ﹤0.01% | 3005 |
|
|
2013
Q2 | $376K | Buy |
+58,477
| New | +$344K | ﹤0.01% | 3004 |
|
Other funds holding SUPN
AC
NAMI
SIMG
Geode Capital Management's SUPN Position: Q2 2026 in Review
Geode Capital Management reduced its Supernus Pharmaceuticals (SUPN) stake by 3.3% in Q2 2026, selling an estimated $2.57M and leaving 1,570,088 shares worth $73M. The position accounts for ﹤0.01% of the portfolio, ranked #1415.
Geode Capital Management first reported a position in SUPN in Q2 2013 and has held it in 53 quarters since. The position peaked at $83.9M in Q1 2026. 311 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.
- Geode Capital Management held 1,570,088 shares of Supernus Pharmaceuticals worth $73M as of Q2 2026.
- Geode Capital Management sold 53,426 Supernus Pharmaceuticals shares in Q2 2026, an estimated $2.57M.
- Supernus Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #1415 holding.
- Geode Capital Management first reported a position in Supernus Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Geode Capital Management's Supernus Pharmaceuticals position peaked at $83.9M in Q1 2026.
- 311 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.
Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.